When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven?
When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven?
We feel now is a pretty good time to analyse Evolus, Inc.'s (NASDAQ:EOLS) business as it appears the company may be on the cusp of a considerable accomplishment. Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. With the latest financial year loss of US$62m and a trailing-twelve-month loss of US$53m, the US$963m market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on Evolus' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
我們認爲現在是分析evolus, inc. (納斯達克:EOLS) 業務的一個相當不錯的時機,因爲該公司似乎可能即將取得重大成就。 evolus, inc.是一家專注於在美國、加拿大和歐洲現金美學市場提供產品的表現美容公司。最新財政年度虧損爲6200萬美元,過去十二個月虧損爲5300萬美元,市值96300萬美元的公司通過朝着實現盈虧平衡的目標邁出了減少虧損的步伐。由於盈利路徑是evolus投資者關注的話題,我們決定來衡量市場情緒。我們彙編了該公司的業內分析師對公司、實現盈虧平衡的年份以及暗含增長率的簡要概述。
According to the 6 industry analysts covering Evolus, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$37m in 2026. Therefore, the company is expected to breakeven roughly 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 69% is expected, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
根據6位覆蓋evolus的行業分析師的觀點,他們一致認爲盈虧平衡即將到來。他們預計該公司將在2025年錄得最終虧損,然後在2026年實現3700萬美元的正利潤。因此,預計該公司將在大約2年後實現盈虧平衡。爲了達到這個盈虧平衡日期,我們計算了公司必須保持年增長速率。結果顯示,預計年均增長率爲69%,這相當樂觀!如果該業務增長速度較慢,那麼它將在預期之後的某個日期才會盈利。
Given this is a high-level overview, we won't go into details of Evolus' upcoming projects, but, bear in mind that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
鑑於這只是一個高層次的概述,我們不打算詳細介紹evolus的即將推出的項目,但請記住,一般來說,製藥公司根據產品開發階段,現金流波動不定。因此,高增長率並不奇怪,尤其是當公司正處於投資期時。
One thing we would like to bring into light with Evolus is its debt-to-equity ratio of over 2x. Generally, the rule of thumb is debt shouldn't exceed 40% of your equity, and the company has considerably exceeded this. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.
我們希望提醒大家關注evolus的一件事,那就是其超過2倍的負債權益比。一般來說,經驗法則是負債不應超過您的股權的40%,而該公司已經大大超出了這一比例。更高水平的債務需要更嚴格的資本管理,這增加了投資這家虧損公司的風險。
Next Steps:
下一步:
There are key fundamentals of Evolus which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Evolus, take a look at Evolus' company page on Simply Wall St. We've also put together a list of essential factors you should further examine:
Evolus還有一些關鍵實質內容沒有在這篇文章中介紹,但我們必須再次強調,這只是一個基本概述。如果您想要更全面地了解Evolus,請查看Simply Wall St上的Evolus公司頁面。我們還整理了一個您應該進一步審查的重要因素清單:
- Valuation: What is Evolus worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Evolus is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Evolus's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Evolus今日值多少錢?未來的增長潛力已經被市場充分考慮到了嗎?我們的免費研究報告中的內在價值信息圖可以幫助您可視化Evolus當前是否被市場定價錯誤。
- 管理團隊:一個經驗豐富的管理團隊可以增加我們對這個企業的信心-請看看誰在Evolus董事會和CEO的背景。
- 其他高表現的股票:是否有其他表現更好的股票並具有經過驗證的歷史記錄?查看這裏的免費列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。